

# Biochemical and Biophysical Research Communications

**Peter (P.W.) Andrews**

Department of Biomedical Science  
University of Sheffield  
Sheffield, UK

**Wolfgang Baumeister**

Abteilung Molekulare Strukturbioogie  
Max-Planck-Institut für Biochemie  
Martinsried, Germany

**Ernesto Carafoli**

*Editor-in-Chief*  
Venetian Institute of Molecular  
Medicine (VIMM)  
University of Padova, Italy

**Chin Ha Chung**

School of Biological Sciences  
College of Natural Sciences  
Seoul National University  
Seoul  
Republic of Korea

**Zengyi Chang**

Biochemistry and Molecular Biology  
School of Life Sciences  
Center of Protein Science  
Peking University Beijing, China

**Vitaly Citovsky**

Department of Biochemistry and  
Cell Biology  
State University of New York  
Stony Brook, NY, USA

**Bengt Fadeel**

Division of Molecular Toxicology  
Institute of Environmental Medicine  
Karolinska Institutet Stockholm, Sweden

**Barry Halliwell**

Biochemistry Department  
National University of Singapore  
Singapore, Singapore

**Cecilia Hidalgo**

Faculty of Medicine  
University of Chile Santiago, Chile

**Hans Jornvall**

Department of Medical Biochemistry  
and Biophysics  
Karolinska Institutet  
Stockholm, Sweden

**Claude Klee**

Laboratory of Biochemistry  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland, USA

**Guido Kroemer**

INSERM, U848  
Institut Gustave Roussy  
Villejuif, France

**William J. Lennarz**

Department of Biochemistry and  
Cell Biology  
State University of New York  
at Stony Brook  
Stony Brook, New York, USA

**Michael Lichten**

Laboratory of Biochemistry and  
Molecular Biology, Center for Cancer Research,  
National Cancer Institute, US

**Anders (A.H.) Lund**

Biotech Research and Innovation Centre  
University of Copenhagen  
Copenhagen, Denmark

**Carlos Martínez-A**

Department of Immunology and Oncology  
National Center for Biotechnology  
Campus Universidad Autonoma  
28049 Madrid, Spain

**Hisao Masai**

Director of Center for Basic Technology  
Research, Genome Dynamics Project  
Department of Genome Medicine  
Tokyo Metropolitan Institute of Medical  
Science, Tokyo, Japan

**Satyajit Mayor**

Cellular Organization and Signalling Group  
National Centre for Biological Science  
(NCBS), UAS-GKVK Campus  
Karnataka, India

**Katsuhiko K. Mikoshiba**

RIKEN  
Laboratory for Development  
Neurobiology, Japan

**Davis Ng**

Temasek Life Sciences Laboratory  
National University of Singapore  
Singapore, Singapore

**James M. Ntambi**

Departments of Biochemistry and  
Nutritional Sciences  
University of Wisconsin-Madison  
Madison WI 53706, USA

**Sten Orrenius**

Institutet of Environmental Medicine  
Karolinska Institutet  
Stockholm, Sweden

**Jacques Pouyssegur**

UMR 6543 CNRS  
Centre Antoine Lacassagne  
Nice, France

**Igor Stagljar**

Department of Molecular Genetics and  
Biochemistry  
University of Toronto  
Toronto, Ontario, Canada

**Bing Su**

Department of Immunology and  
Microbiology, Shanghai Institute of  
Immunology, China

**Kiyoshi Takatsu**

Department of Immunology  
Institute of Medical Science  
University of Tokyo, Tokyo, Japan

**Naoyuki Taniguchi**

Systems Glycobiology Research Group  
RIKEN Global Research Cluster  
Wako, Japan

**Anna Tramontano**

Department of Physics  
Sapienza University of Rome  
Rome, Italy

**Olga Troyanskaya**

Department of Computer Science and  
Lewis-Sigler Institute for Integrative  
Genomics Princeton University,  
New Jersey, USA

**Isaac P. Witz**

Tel Aviv University  
Tel Aviv, Israel

*Correspondence regarding production may be sent to:*

**Biochemical and Biophysical Research Communications, Elsevier Inc.**

International Tech Park, Crest – 12th Floor, CSIR Road, Taramani, Chennai 600 113, India

Tel: +91 44 42994826, Fax: +91 44 42994568, E-mail [bbrc@elsevier.com](mailto:bbrc@elsevier.com)



**Cover photo.** Hypothetical model of the mechanisms involved in AIF processing and release. Exposure of NSCLC cells to the protein kinase C inhibitors, staurosporine or PKC412, results in a hyperpolarization of the plasma membrane. As a consequence, the hyperpolarization-activated HCN2 channel opens and permits  $\text{Ca}^{2+}$  to enter the cell. Both plasma membrane hyperpolarization and the activation of HCN2 channel are inhibited by  $\text{Cs}^+$ . The resulting  $\text{Ca}^{2+}$  elevation in the cytosol also translocates to the intermembrane space of the mitochondria and results in the activation of calpain as well as enhanced ROS formation. The calcium chelator, BAPTA is able to inhibit both calpain activation and ROS accumulation, whereas only the latter is inhibited by NAC and Trolox. AIF is cleaved by mitochondrial calpain-I. This cleavage is prevented by PD150606, a selective calpain inhibitor. Cleaved AIF is released into the cytosol and translocates to the nucleus, where it contributes to chromatin condensation and highmolecular weight DNA fragmentation. Nuclear translocation of AIF can be inhibited by binding to Hsp70 in the cytosol. (BBRC Volume 396, pages 95–100). It is reproduced by kind permission of the authors – Sten Orrenius, et al.